drugset / Trial / NCT05112939
A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to characterize the single dose pharmacokinetics (PK) and evaluate the safety and tolerability of subcutaneous administration of rilpivirine (RPV) long-acting (LA) or RPV LA in combination with cabotegravir (CAB) LA extended release suspensions in different conditions in healthy adult participants.
Timeline
- Start
- 2021-11-16
- Primary completion
- 2024-05-23
- Completion
- 2024-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabotegravir | Small molecule | — | Subcutaneous |
| Subject | Rilpivirine | Small molecule | — | Subcutaneous |
Indications
No indication recorded.